Express News | Lipella Pharmaceuticals Completes Site Initiation Visit For Phase 2a Trial Of LP-310 In Oral Lichen Planus; Clinical Testing Of LP-310 Expected To Commence In Mid 2024
Express News | Lipella Pharmaceuticals Inc -Study Is Anticipated to Conclude in Mid-2025
Express News | Lipella Pharmaceuticals Inc -Patient Recruitment Is Underway for Phase 2a Multicenter, Dose-Ranging Study
Express News | Lipella Pharmaceuticals Inc - Clinical Testing of LP-310 Expected to Commence in Mid-2024
Express News | Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersMustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASD
Express News | Lipella Pharmaceuticals-Sees to Initiate Phase 2B Clinical Trial Evaluating LP-10 as Treatment for Hemorrhagic Cystitis in H2 2024
Express News | Following Guidance From U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2B
Following Guidance From U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug
Clearside Biomedical And 3 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and trade
Lipella Pharmaceuticals(LIPO.US) 10% Shareholder Buys US$7,590 in Common Stock
$Lipella Pharmaceuticals(LIPO.US)$ 10% Shareholder Kaufman Jonathan H purchased 10,000 shares of common stock on May 14, 2024 at an average price of $0.759 for a total value of $7,590.Source: Announce
Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 Loss per Share (Vs US$0.19 Loss in 1Q 2023)
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of Natera, Inc. (NASDAQ:NTRA) rose sharply in today's pre-market trading following strong first-quarter earnings.
Lipella Pharmaceuticals | 10-Q: Quarterly report
Express News | Lipella Pharmaceuticals Expands Its Advisory Board to Include Oncology Expertise
Express News | Maxim Group Initiates Coverage On Lipella Pharmaceuticals With Buy Rating, Announces Price Target of $2
Lipella Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 185.92% Maxim Group → $2 Initiates Coverage On → Buy
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant
No Data